In short
Clinical trials are studying Lutetium (177Lu) Vipivotide Tetraxetan in several cancer settings, mostly prostate cancer. These studies look at safety, effectiveness, and long-term outcomes in different patient groups, including men with metastatic, hormone-sensitive, castration-resistant, localized, and very high-risk disease.
Key points
- Lutetium (177Lu) Vipivotide Tetraxetan is being studied mainly in prostate cancer, especially PSMA-positive disease. The trial data include Phase 1, Phase 2, Phase 3, and one Phase IV safety study. Researchers are looking at how well the treatment works, how long it delays progression, and how safe it is over time. Some studies also test it in earlier disease, such as localized, high-risk, or hormone-sensitive prostate cancer. A few trials include other cancers, such as clear cell renal cell carcinoma and adenoid cystic carcinoma. The studies use outcomes like PSA response, survival, scan-based progression, and adverse events.
Trial overview
These studies investigate Lutetium (177Lu) Vipivotide Tetraxetan in people with different types of cancer, mostly prostate cancer. The trials are designed to check whether the treatment can improve cancer control, delay progression, and remain safe in different patient groups.
Prostate cancer studies
Most trials focus on prostate cancer, especially PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Some studies look at earlier disease stages, including metastatic hormone-sensitive prostate cancer, oligometastatic prostate cancer, high-risk localized disease, locally advanced disease, and very high-risk prostate cancer.
Several phase 3 studies compare Lutetium (177Lu) Vipivotide Tetraxetan with standard care, observation, or a change in androgen receptor-directed therapy. These studies are trying to see whether the treatment can improve outcomes such as overall survival, radiographic progression-free survival, and metastasis-free survival.
Some prostate cancer trials test the treatment together with other medicines, such as androgen receptor pathway inhibitors or ipilimumab. Other studies look at re-treatment, neoadjuvant use before surgery, or use after radical treatment and hormone therapy.
Other cancers studied
Not all studies are in prostate cancer. One phase 2 trial studies clear cell renal cell carcinoma, and another phase 2 trial studies adenoid cystic carcinoma from the salivary glands. These studies help researchers learn whether the treatment may have a role in other PSMA-related or radiopharmaceutical research settings.
Study phases and participants
The trial list includes Phase 1, Phase 2, Phase 3, and one Phase IV post-authorization safety study. Early-phase studies usually focus on safety, tolerability, feasibility, and dosimetry, while later-phase studies focus more on effectiveness and long-term outcomes.
Participant groups vary by study. Some trials include adults with PSMA-positive disease, some require prior treatment exposure, and some focus on people with normal kidney function or renal impairment. A few trials include men who are candidates for radical prostatectomy, meaning surgery to remove the prostate gland.
Main endpoints and what they mean
The studies measure several main endpoints, which are the main results researchers want to learn about. Common endpoints include PSA50 rate, PSA response, objective response, biochemical failure, metastasis-free survival, radiographic progression-free survival, and overall survival.
PSA50 means a drop of at least 50% in prostate-specific antigen from baseline, which is the level before treatment starts. Objective response means a complete or partial shrinkage of cancer seen on imaging, and biochemical failure means the PSA level rises in a way that suggests the cancer is returning or worsening.
Some trials also measure dosimetry, which checks how radiation is distributed in the body, especially in organs such as the kidneys. Safety endpoints often count adverse events, serious adverse events, lab changes, dose interruptions, dose reductions, and treatment discontinuation.
Safety and long-term follow-up
Safety is a major part of the research program. One phase 4 study follows adult participants with prostate cancer for long-term safety after authorization, including selected adverse events and serious adverse events. The brief summary for this study says it is meant to further characterize long-term outcomes, including known or potential risks such as myelosuppression, renal failure, dry mouth, dry eyes, and secondary malignancies like myelodysplastic syndrome and acute myeloid leukemia.
Other trials also focus on tolerability, which means how well participants can stay on treatment without major dose changes or stopping early. This is important because several studies include repeated treatment cycles or combination treatment plans.